NASDAQ: ANIP | Healthcare / Drug Manufacturers / USA |
57.49 | +0.9900 | +1.75% | Vol 90.37K | 1Y Perf 71.42% |
Oct 4th, 2023 16:00 DELAYED |
BID | 56.04 | ASK | 59.82 | ||
Open | 56.40 | Previous Close | 56.50 | ||
Pre-Market | - | After-Market | 57.55 | ||
- - | 0.06 0.10% |
Target Price | 43.25 | Analyst Rating | Strong Buy 1.00 | |
Potential % | -24.77 | Finscreener Ranking | ★★★★ 52.98 | |
Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | ★★+ 49.02 | |
Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | + 31.62 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 75.78 | Earnings Rating | Strong Buy | |
Market Cap | 1.17B | Earnings Date | 8th Nov 2023 | |
Alpha | 0.00 | Standard Deviation | 0.13 | |
Beta | 1.07 |
Today's Price Range 56.2858.14 | 52W Range 31.2165.89 | 5 Year PE Ratio Range -410.20213.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -2.38% | ||
1 Month | -8.48% | ||
3 Months | 7.54% | ||
6 Months | 49.79% | ||
1 Year | 71.42% | ||
3 Years | 97.36% | ||
5 Years | 4.55% | ||
10 Years | 414.68% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -5.75 | |||
ROE last 12 Months | -29.20 | |||
ROA (5Y Avg) | -1.96 | |||
ROA last 12 Months | -12.16 | |||
ROC (5Y Avg) | 1.02 | |||
ROC last 12 Months | -10.06 | |||
Return on invested Capital Q | -0.65 | |||
Return on invested Capital Y | -4.11 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 1.80 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-9.50 | ||||
2.46 | ||||
3.32 | ||||
100.40 | ||||
-18.50 | ||||
-2.48 | ||||
39.58 | ||||
17.87 | ||||
1.02B | ||||
Forward PE | 16.73 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.40 | ||||
3.80 | ||||
0.46 | ||||
0.92 | ||||
-2.50 | ||||
Leverage Ratio | 2.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
51.80 | ||||
-22.20 | ||||
-1.80 | ||||
-8.50 | ||||
-19.65 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
222.15M | ||||
12.73 | ||||
1.77 | ||||
6.72 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 0.45 | 1.06 | 135.56 |
Q01 2023 | 0.16 | 0.97 | 506.25 |
Q04 2022 | 0.49 | 0.59 | 20.41 |
Q03 2022 | 0.40 | 0.46 | 15.00 |
Q02 2022 | -0.04 | -0.05 | -25.00 |
Q01 2022 | -0.05 | -0.27 | -440.00 |
Q04 2021 | 0.69 | 0.38 | -44.93 |
Q03 2021 | 0.55 | 0.83 | 50.91 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | 0.55 | 10.00 | Positive |
12/2023 QR | 0.68 | 6.25 | Positive |
12/2023 FY | 3.17 | 23.83 | Positive |
12/2024 FY | 3.47 | -1.14 | Negative |
Next Report Date | 8th Nov 2023 |
Estimated EPS Next Report | 0.55 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 90.37K |
Shares Outstanding | 20.29K |
Shares Float | 12.16M |
Trades Count | 3.21K |
Dollar Volume | 5.19M |
Avg. Volume | 142.36K |
Avg. Weekly Volume | 125.48K |
Avg. Monthly Volume | 153.74K |
Avg. Quarterly Volume | 147.86K |
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 56.5 per share at the end of the most recent trading day (a -0.65% change compared to the prior day closing price) with a volume of 80.25K shares and market capitalization of 1.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.
The one-year performance of ANI Pharmaceuticals Inc. stock is 71.42%, while year-to-date (YTD) performance is 42.9%. ANIP stock has a five-year performance of 4.55%. Its 52-week range is between 31.21 and 65.89, which gives ANIP stock a 52-week price range ratio of 75.78%
ANI Pharmaceuticals Inc. currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.46, a price-to-sale (PS) ratio of 3.32, a price to cashflow ratio of 100.40, a PEG ratio of -, a ROA of -12.16%, a ROC of -10.06% and a ROE of -29.20%. The company’s profit margin is -19.65%, its EBITDA margin is -1.80%, and its revenue ttm is $222.15 Million , which makes it $12.73 revenue per share.
Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $43.25, which is -24.77% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ANI Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.65, ATR14 : 1.77, CCI20 : -147.48, Chaikin Money Flow : -0.31, MACD : -0.83, Money Flow Index : 16.27, ROC : -9.44, RSI : 35.55, STOCH (14,3) : 9.86, STOCH RSI : 0.00, UO : 42.22, Williams %R : -90.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Gassert Chad (Sold 20 000 shares of value $1 026 400 ), Shanmugam Muthusamy (Sold 23 469 shares of value $1 220 844 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Moderate Buy |
ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.
CEO: Nikhil Lalwani
Telephone: +1 218 634-3500
Address: 210 Main Street West, Baudette 56623, MN, US
Number of employees: 338
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.